PMID: 6108751Dec 1, 1980Paper

gamma-Acetylenic GABA in tardive dyskinesia

Archives of General Psychiatry
D E CaseyT R Christensen

Abstract

Brain gamma-aminobutyric acid (GABA) has been proposed to play a role in the modulation of extrapyramidal motor function. The effects of increasing brain GABA with gamma-acetylenic GABA (GAG), a drug that inhibits GABA transaminase, were evaluated in ten patients with stable tardive dyskinesia during a blind placebo-controlled trial. Drug effects during active treatment and two placebo periods were evaluated by scoring randomly sequenced videotapes of tardive dyskinesia and parkinsonian symptoms recorded weekly during a standardized examination. Tardive dyskinesia was significantly reduced, and preexisting parkinsonism increased slightly. The largest decrease in tardive dyskinesia symptoms occurred in patients receiving higher neuroleptic doses, suggesting an interaction between GABA and dopamine. Prolactin values increased but growth hormone values were unchanged. Psychiatric symptoms were also unchanged during GAG treatment.

Citations

Dec 1, 1987·Journal of Neurology, Neurosurgery, and Psychiatry·J M GaioJ Perret
Jan 1, 1994·Journal of Neural Transmission. General Section·X M GaoC A Tamminga
Feb 1, 1982·Psychological Medicine·B Meldrum
May 1, 1983·Psychiatry Research·M I LevyK L Davis
Apr 1, 1983·Psychiatry Research·S KorsgaardJ Gerlach
Nov 3, 1998·Biological Psychiatry·M H ChakosC A Tamminga
Jan 1, 1983·Psychopharmacology·N BjørndalE Christensson
Aug 1, 1982·Psychosomatics·K E CallenM I Sorkin
Jan 6, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Young-Min ParkJae-Hyuck Cho
Dec 1, 1982·Annals of Neurology·C N KarsonR J Wyatt
Jun 26, 2013·Nordic Journal of Psychiatry·Woo-Young SonLeen Kim
Nov 6, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Chul-Hyun Cho, Heon-Jeong Lee
Jul 30, 2016·Pharmacogenomics·Rachel K LanningDaniel J Müller
Jun 1, 1994·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·K L Behar, D Boehm
Sep 3, 1981·The New England Journal of Medicine·M SantoshamR Black
May 11, 2006·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·William R Marchand, Valentina Dilda
Jan 1, 1992·Journal of Psychopharmacology·T R Barnes
Mar 13, 2018·Current Opinion in Psychiatry·Clement C ZaiJames L Kennedy
Nov 19, 2003·Journal of Clinical Psychopharmacology·Adel WassefLisa D Kochan
Apr 18, 2018·The Cochrane Database of Systematic Reviews·Samer AlabedHanna Bergman
Jan 1, 1985·Folia Psychiatrica Et Neurologica Japonica·K KashiharaS Otsuki
Jan 1, 1980·Psychopharmacology·N BjørndalJ Gerlach
Jan 1, 1980·Psychopharmacology·D E CaseyE Christensson
Apr 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·G G Fisk, S M York
Jun 1, 1999·Journal of Clinical Psychopharmacology·A A WassefR M Rose
Apr 15, 2011·The Cochrane Database of Systematic Reviews·Samer AlabedAbdullah Rifai
Aug 20, 2019·Current Neurology and Neuroscience Reports·Divya AryaHubert H Fernandez
Oct 1, 1983·The British Journal of Psychiatry : the Journal of Mental Science·B M Crowe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here